Phase Ib/II Clinical Study of Adebrelimab in Combination With Decitabine, Albumin-bound Paclitaxel, and Gemcitabine for the First-line Treatment of Metastatic Pancreatic Cancer

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 15, 2024

Primary Completion Date

June 30, 2025

Study Completion Date

November 30, 2026

Conditions

Adebrelimab (SHR-1316)DecitabineMetastatic Pancreatic Cancer

Interventions

DRUG

Adebrelimab;decitabine;

Adebrelimab:1200 mg Decitabine:10mg/m2 or 15mg/m2

Trial Locations (1)

RECRUITING

Tianjin Medical University Cancer Institute and Hospital, Tianjin

All Listed Sponsors

lead

Tianjin Medical University Cancer Institute and Hospital

OTHER